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millions of individuals?
Peter M Visscher1* and Greg Gibson2The affordable whole-genome sequence is (nearly) here
and already costs less than many commercial DNA tests
for specific variants or genes. It seems very plausible to
us that in the near future millions of people will have
their genome sequenced, not just because the cost is
coming down but also because individuals (in rich coun-
tries) are increasingly becoming ‘health consumers’.
Here, we muse on what we could infer from having
whole-genome sequence data for a million individuals.
In the absence of phenotypic data, there are six types
of information that people can obtain from their own
genomes. Firstly, their ancestry: how their chromosomes
compare with those of typical members of diverse hu-
man populations. Secondly, things they can do some-
thing about (for example, enzyme deficiencies, BRCA1-
like mutations, their pharmacogenetic responses).
Thirdly, things they are unable to do anything about,
most of which will be a source of anxiety [1]. Fourthly,
things that explain interesting or medical phenotypes
(for example, eye color or rare congenital traits). Fifthly,
things they may worry about handing on to their chil-
dren (and which they might want to check in their (pro-
spective) spouse or prevent their children from being at
high risk for). Finally, things they may like to pass on to
their children. The first four types of information in this
list relate to the person whose genome has been se-
quenced, the last two are about their children. Of this
list, (2) and (5) lead to information that is, from a health
perspective, actionable right now. At present, most
knowledge on these actionable items are restricted to
Mendelian traits.Actionable Mendelian variants now and in the
future
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© 2013 BioMed Central Ltd.magnitude larger than the number of homozygotes. For
example, for a recessive Mendelian disease with a preva-
lence of one in a million, we would expect to find a sin-
gle person who has the disease among our sample of 1
million people whose whole genomes were sequenced,
but we would also expect to find about 2,000 people
who are carriers. If we were to check their spouses, then
on average 1 in 250,000 couples would discover that they
are both carriers. These frequencies are just for one very
rare disease; in fact, more than 1,000 genes have been
identified that cause recessive Mendelian diseases and
each person is a carrier for a number of these [2], so that
about 1 in 25 couples can expect to discover that they
share at least one mutation that has a non-trivial chance
of resulting in their offspring having a severe congenital
disorder. It seems likely that many individuals or couples
will avail themselves of the opportunity to prepare for
this possibility by having their genomes sequenced.Limits of disease susceptibility prediction from
sequence data
For common diseases, it will soon be possible to gener-
ate genomic risk profiles from the genome sequence,
using existing knowledge from genome-wide association
studies (GWAS) about multiple risk variants for a dis-
ease or complex trait. Prediction of individual risk of dis-
ease is not accurate at present because, for most
diseases, only a small proportion of genetic variation in
risk between people has been accounted for by known
genetic variants. There is also a limit to how well a gen-
etic predictor can ever work [3,4] because common dis-
ease is caused by the combination of genetic and
environmental factors.
For complex traits, the upper limit of the correlation
between an as-yet-unobserved phenotype and a genetic
predictor for an individual is h, the square root of the
proportion of phenotypic variation that is attributable to
genetic variation (or the trait’s heritability (h2)). For most
complex human traits, h2 falls in the range of 40 to 80%,
so the upper limit of the precision of prediction is about
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of the variants in the genome that affect risk and have esti-
mated their effect sizes without error. To put the (in)ac-
curacy of such genetic prediction into perspective,
imagine if we had a perfect genetic predictor for height (in
which all causal variants are known without error). Then,
assuming that h2 = 80% and that the standard deviation
for height is 7 cm, the prediction error [5] for any individ-
ual would be 7 × √(1–0.8) = 3.1 cm. So we would predict
someone’s height with a 95% confidence interval of about
± 6 cm. With discovery data on 1 million genomes, a the-
oretical prediction of the prediction error is about 3.5 cm
[6], not far off the minimum value possible.
What about making predictions about children who
have not had their genomes sequenced (for example, be-
cause they have not been born yet)? Now the precision
of prediction decreases further because we cannot pre-
dict from knowing the parental genome sequences
which combination of risk alleles the children are going
to inherit. The added amount of uncertainty is not triv-
ial: of all genetic variation in the population, 50% occurs
between siblings within families.
A useful comparison at this stage is to look at how
animal breeders perform genetic predictions. They are
mostly interested in item (6) from our list of genomic in-
formation types, and use DNA markers to make imper-
fect predictions that are used in selection decisions. This
approach makes better predictions than the pedigree-
phenotype-based approach used previously. Their busi-
ness is about making money from having a progeny gen-
eration that is, on average, genetically better than the
parental generation [7]. Breeders do not worry about
quantifying how well they can predict an individual’s
phenotype because they are interested in predicting ge-
notypes and thereby the average phenotype of progeny.
We think it unlikely that humans will select their part-
ner on the basis of genome-based polygenic predictors
with an eye to maximizing the odds that all of their chil-
dren are superior in some way (although something like
this does occur when sperm banks are used).
What might be the utility of risk scores derived
from the study of millions of genomes?
To some extent, this comes down to the question of
whether it is prediction or classification that matters.
For the millions of individuals who are assembling
health action plans, and indulging in the self-knowledge
provided by software applications that aim to promote
personal fitness, it is more about skewing the odds than
predicting the future. Given a prediction, whether or not
someone ever gets diabetes or coronary disease is less
important than having the knowledge that they have
gained influence their behaviors in ways that make it less
likely that they will get these diseases. In this light,knowing the aspects of your health in which you are
genetically at higher risk than the rest of the population
might well be just the incentive you need to keep jog-
ging, to strive for more alcohol-free days, or to screen
for cancer more regularly.
What if the millions of sequences came with detailed
phenotype data? For example, this could comprise dis-
ease status for a range of common diseases and mea-
sures on quantitative traits that are risk factors for
disease. This is not a far-fetched scenario. The Kaiser
Permanente and University of California, San Francisco
(UCSF) collaboration [8] has obtained detailed
phenotyped and genotyped data for over 100,000 people,
and earlier this year, it was announced that the UK
Biobank sample of 500,000 people will be genotyped
using a single-nucleotide polymorphism (SNP) array [9].
Phenotype and sequence data for a million people will
allow the discovery of more risk and trait variants and
the creation of multiple-variant profiles that can be used
for prediction. But is a million sequences enough? For
diseases with a prevalence of about 1%, there will be
10,000 cases among the million. Larger GWAS samples
already exist for some diseases, such as Crohn’s disease
and schizophrenia. Although these have identified tens
to hundreds of risk variants, polygenic profiles explain
only a modest proportion of risk in the population, al-
though they can do better than self-reported ‘family his-
tory’ [10]. Sequence data (instead of solely relying on
common variants from GWAS) will improve the predic-
tion of disease by capturing variation resulting from
lower-frequency risk variants. With millions of genomes
sequenced, the limitation of disease prediction for many
traits is likely to result from imperfect information on
environmental effects. The question is therefore not
‘how well can we predict disease’ but ‘how can we in-
corporate probabilistic predictions of disease in personal
or clinical decision making’. There are plenty of chal-
lenges on the way, including the generation of accurate
sequence data, getting all these data together for ana-
lysis, and the statistical analysis of millions of genome
sequences. Then, there will be the practical challenges of
disseminating the results, not to mention encouraging
people to act on them for the benefit of their health.
For quantitative traits and disease, we can expect
major advances in our ability to explain the genetic com-
ponent of disease risk and thus to predict disease. What
we do with that information is a sociological concern
with major public health implications, and now is the
time to contemplate the implications.
Abbreviation
GWAS: Genome-wide association study.
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